An Assessment of Semaglutide Safety Based on Real World Data: From Popularity to Spontaneous Reporting in EudraVigilance Database

Some glucagon-like peptide-1 receptor agonists (GLP-1 RAs), first used in the treatment of type 2 diabetes mellitus (T2DM), have been approved for the treatment of obesity in patients with or without T2DM (liraglutide—LIR, semaglutide—SEM, and tirzepatide—TIR). Social media had an important influenc...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Anca Butuca, Carmen Maximiliana Dobrea, Anca Maria Arseniu, Adina Frum, Adriana Aurelia Chis, Luca Liviu Rus, Steliana Ghibu, Anca Maria Juncan, Andrei Catalin Muntean, Antonina Evelina Lazăr, Felicia Gabriela Gligor, Claudiu Morgovan, Andreea Loredana Vonica-Tincu
Formato:	Artigo
Idioma:	Inglês
Publicado em:	MDPI AG 2024-05-01
coleção:	Biomedicines
Assuntos:	semaglutide obesity weight loss overdose underdose off-label use
Acesso em linha:	https://www.mdpi.com/2227-9059/12/5/1124
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!